Literature DB >> 32303334

Distinct roles of calmodulin and Ca2+/calmodulin-dependent protein kinase II in isopreterenol-induced cardiac hypertrophy.

Siqi Wang1, Jingyuan Li1, Yan Liu1, Jie Zhang1, Xi Zheng1, Xuefei Sun1, Shuai Lei1, Ze Kang1, Xiye Chen1, Ming Lei2, Huiyuan Hu1, Xiaorong Zeng3, Liying Hao4.   

Abstract

Intracellular calcium is related to cardiac hypertrophy. The CaV1.2 channel and Ca2+/calmodulin-dependent protein kinase II (CaMKII) and CaM regulate the intracellular calcium content. However, the differences in CaMKII and CaM in cardiac hypertrophy are still conflicting and are worthy of studying as drug targets. Therefore, in this study, we aim to investigate the roles and mechanism of CaM and CaMKII on CaV1.2 in pathological myocardial hypertrophy. The results showed that ISO stimulation caused SD rat heart and cardiomyocyte hypertrophy. In vivo, the HW/BW, LVW/BW, cross-sectional area, fibrosis ratio and ANP expression were all increased. There were no differences in CaV1.2 channel expression in the in vivo model or the in vitro model, but the ISO stimulation induced channel activity, and the [Ca2+]i increased. The protein expression levels of CaMKII and p-CaMKII were all increased in the ISO group, but the CaM expression level decreased. AIP inhibited ANP, CaMKII and p-CaMKII expression, and ISO-induced [Ca2+]i increased. AIP also reduced HDAC4, p-HDAC and MEF2C expression. However, CMZ did not play a cardiac hypertrophy reversal role in vitro. In conclusion, we considered that compared with CaM, CaMKII may be a much more important drug target in cardiac hypertrophy reversal.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ca(2+)/calmodulin-dependent protein kinase II; Ca(V)1.2; Calmodulin; Cardiac hypertrophy

Year:  2020        PMID: 32303334     DOI: 10.1016/j.bbrc.2020.03.188

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Atherogenic L5 LDL induces cardiomyocyte apoptosis and inhibits KATP channels through CaMKII activation.

Authors:  Yanzhuo Ma; Nancy Cheng; Junping Sun; Jonathan Xuhai Lu; Shahrzad Abbasi; Geru Wu; An-Sheng Lee; Tatsuya Sawamura; Jie Cheng; Chu-Huang Chen; Yutao Xi
Journal:  Lipids Health Dis       Date:  2020-08-21       Impact factor: 3.876

2.  CaMKII inhibitor KN-93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p-VEGFR2 and STAT3 pathways.

Authors:  Yajuan Ni; Jie Deng; Hongyuan Bai; Chang Liu; Xin Liu; Xiaofang Wang
Journal:  J Cell Mol Med       Date:  2021-11-29       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.